The use of cationic MPEG-PCL-g-PEI micelles for co-delivery ofMsurvivin T34A gene and doxorubicin

Biomaterials

Volumn 35, Issue 15, 2014, Pages 4536-4547

  Shi, Shuai ^a,b   Shi, Kun ^a   Tan, LiWei ^a   Qu, Ying ^a   Shen, GuoBo ^a   Chu, BingYang ^a   Zhang, Shuang ^a   Su, XiaoLan ^a   Li, XingYi ^b   Wei, YuQuan ^a   Qian, ZhiYong ^a  

^a SICHUAN UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cancer therapy; Cationic micelles; Co delivery vector; Triblock copolymer

Indexed keywords

BIOLOGICAL ORGANS; BLOCK COPOLYMERS; CELL DEATH; CHEMOTHERAPY; GENES; PATHOLOGY; TOXICITY; TUMORS;

ANTI-TUMOR ACTIVITIES; CANCER THERAPY; CATIONIC MICELLES; CHEMOTHERAPEUTIC AGENTS; CO DELIVERIES; PHYSICOCHEMICAL PROPERTY; SUBCUTANEOUS TUMOR MODELS; SYSTEMIC TOXICITIES;

MICELLES;

COPOLYMER; DOXORUBICIN; MACROGOL; POLYCAPROLACTONE; POLYETHYLENEGLYCOL POLYCAPROLACTONE POLYETHYLENEIMINE; POLYETHYLENEIMINE; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD COMPATIBILITY; BODY DISTRIBUTION; CANCER GENE THERAPY; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG METASTASIS; MICELLE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; SKIN TUMOR; TOXICITY; TUMOR CELL;

CANCER THERAPY; CATIONIC MICELLES; CO-DELIVERY VECTOR; TRIBLOCK COPOLYMER;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CATIONS; CELL LINE, TUMOR; DNA; DOXORUBICIN; DRUG CARRIERS; FEMALE; GENETIC THERAPY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED BALB C; MICELLES; NEOPLASMS; POLYESTERS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; REPRESSOR PROTEINS; TRANSFECTION;

EID: 84896051260     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.02.010     Document Type: Article

References (33)

1. Venkataraman S., Hedrick J.L., Ong Z.Y., Yang C., Ee P.L.R., Hammond P.T., et al. The effects of polymeric nanostructure shape on drug delivery. Adv Drug Deliv Rev 2011, 63:1228-1246.
2. Dobson J. Nanomedicine for targeted drug delivery. JMater Chem 2009, 19:6294-6307.
3. Riehemann K., Schneider S.W., Luger T.A., Godin B., Ferrari M., Fuchs H. Nanomedicine-challenge and perspectives. Angew Chem Int Ed Engl 2009, 48:872-897.
4. Wang B., He X., Zhang Z., Zhao Y., Feng W. Metabolism of nanomaterials invivo: blood circulation and organ clearance. Acc Chem Res 2012, 46:761-769.
5. Matsumura Y., Maeda H. Anew concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
6. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
7. Wang X., Yang L., Chen Z.G., Shin D.M. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 2008, 58:97-110.
8. Rösler A., Vandermeulen G.W.M., Klok H.A. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev 2012, 53:95-108.
9. Duan X.M., Wang P., Men K., Gao X., Huang M.J., Gou M.L., et al. Treating colon cancer with a suicide gene delivered by self-assembled cationic MPEG-PCL micelles. Nanoscale 2012, 4:2400-2407.
10. Xue B., Wang Y., Tang X.H., Xie P., Luo F., Wu C., et al. Biodegradable self-assembled MPEG-PCL micelles for hydrophobic oridonin delivery invitro. JBiomed Nanotechnol 2012, 8:80-89.
11. Gong C., Deng S., Wu Q., Xiang M., Wei X., Li L., et al. Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable polymeric micelles. Biomaterials 2012, 34:1413-1432.
12. Creixell M., Peppas N.A. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 2012, 7:367-379.
13. Yue X., Qiao Y., Qiao N., Guo S., Xing J., Deng L., et al. Amphiphilic methoxy poly (ethylene glycol)-b-poly (ε-caprolactone)-b-poly (2-dimethylaminoethyl methacrylate) cationic copolymer nanoparticles as a vector for gene and drug delivery. Biomacromolecules 2010, 11:2306-2312.
14. Shi S., Fan M., Wang X., Zhao C., Wang Y., Luo F., et al. Synthesis and characterization of mPEG-PCL-g-PEI and self-assembled nanoparticle uptake invitro and invivo. JPhys Chem C 2010, 114:21315-21321.
15. Shi S., Zhu X., Guo Q.F., Wang Y., Zuo T., Luo F., et al. Self-assembled mPEG-PCL-g-PEI micelles for simultaneous codelivery of chemotherapeutic drugs and DNA: synthesis and characterization invitro. Int J Nanomedicine 2012, 7:1749-1759.
16. Liu Y., Samsonova O., Sproat B., Merkel O., Kissel T. Biophysical characterization of hyper-branched polyethylenimine-graft-polycaprolactone-block-mono-methoxyl-poly (ethylene glycol) copolymers (hy-PEI-PCL-mPEG) for siRNA delivery. JControl Release 2011, 153:262-268.
17. Cuong N.V., Hsieh M.F., Chen Y.T., Liau I. Synthesis and characterization of PEG-PCL-PEG triblock copolymers as carriers of doxorubicin for the treatment of breast cancer. JAppl Polym Sci 2010, 117:3694-3703.
18. Cai S., Thati S., Bagby T.R., Diab H.-M., Davies N.M., Cohen M.S., et al. Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. JControl Release 2010, 146:212-218.
19. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy: from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007, 49(5):330-352.
20. Burtles D.J. Kerr. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. JClin Oncol 2002, 20:1668-1676.
21. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 1999, 5:83-94.
22. McKay T.R., Bell S., Tenev T., Stoll V., Lopes R., Lemoine N.R., et al. Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy. Oncogene 2003, 22:3539-3547.
23. Aspe J.R., Wall N.R. Survivin-T34A: molecular mechanism and therapeutic potential. Onco Targets Ther 2010, 3:247-254.
24. Grossman D., Kim P.J., Schechner J.S., Altieri D.C. Inhibition of melanoma tumor growth invivo by survivin targeting. Proc Natl Acad Sci U S A 2001, 98:635-640.
25. Xiao W., Chen X., Yang L., Mao Y., Wei Y., Chen L. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome. Int J Pharm 2010, 393:120-127.
26. Gou M.L., Zheng X.L., Men K., Zhang J., Zheng L., Wang X.H., et al. Poly (ε-caprolactone)/poly (ethylene glycol)/poly (ε-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery. JPhys Chem B 2009, 113:12928-12933.
27. Wang Y., Gao S., Ye W.H., Yoon H.S., Yang Y.Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006, 5:791-796.
28. Chen A.M., Zhang M., Wei D., Stueber D., Taratula O., Minko T., et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5:2673-2677.
29. Liu S., Guo Y., Huang R., Li J., Huang S., Kuang Y., et al. Gene and doxorubicin co-delivery system for targeting therapy of glioma. Biomaterials 2012, 33:4907-4916.
30. Biswas S., Deshpande P.P., Navarro G., Dodwadkar N.S., Torchilin V.P. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials 2012, 34:1289-1301.
31. Xiao Y., Jaskula-Sztul R., Javadi A., Xu W., Chen H., Gong S. Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. Nanoscale 2012, 4:7185-7193.
32. Taurin S., Nehoff H., Greish K. Anticancer nanomedicine and tumor vascular permeability; where is the missing link?. JControl Release 2012, 164:265-275.
33. Sun Q., Radosz M., Shen Y. Challenges in design of translational nanocarriers. JControl Release 2012, 164:156-169.